MNKDHIGH SIGNALFINANCIAL10-K

MNKD's debt exploded 884% to $355M while net income collapsed 79% and operating cash flow declined 57%, indicating potential financial distress despite asset growth from likely acquisitions.

The massive debt increase combined with deteriorating profitability and cash generation suggests MNKD may have made a debt-financed acquisition or faced significant operational challenges. The company's financial flexibility has been severely compromised, raising concerns about its ability to service this debt load given the weakened cash flows.

Comparing 2026-02-26 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

MNKD's financial profile deteriorated significantly with total debt skyrocketing 884% to $355M while profitability collapsed (net income down 79% and operating cash flow down 57%). Though total assets doubled suggesting potential acquisitions, the company's liabilities grew faster than assets, and increased interest expense of 59% reflects the heavy debt burden. The combination of massive leverage increase with weakening operational performance and cash generation creates a concerning financial picture that signals potential distress.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
+883.7%
$36.1M$354.6M

Debt increased 883.7% — substantial leverage increase; assess whether deployed for growth or covering losses.

Accounts Receivable
Balance Sheet
+225%
$11.8M$38.4M

Receivables surged 225% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Liabilities
Balance Sheet
+109%
$81.8M$171.0M

Current liabilities surged 109% — significant near-term obligations; verify ability to meet short-term debt.

Total Assets
Balance Sheet
+101.1%
$393.8M$792.2M

Asset base grew 101.1% — expansion through organic growth, acquisitions, or capital deployment.

Net Income
P&L
-78.7%
$27.6M$5.9M

Net income declined 78.7% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
+78.4%
$472.7M$843.2M

Liabilities grew 78.4% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
+61.6%
$46.3M$74.9M

Cash position surged 61.6% — strong cash generation or capital raise providing significant financial cushion.

Interest Expense
P&L
+58.6%
$9.6M$15.2M

Interest expense surged 58.6% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
-57.1%
$42.5M$18.3M

Operating cash flow fell 57.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Capital Expenditure
Cash Flow
-52.9%
$9.7M$4.6M

Capex reduced 52.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-26
ADDED
As of February 13, 2026, there were 308,100,433 shares of the registrant s Common Stock outstanding.
Afrezza, Technosphere , BluHale , Dreamboat , Furoscix, Furoscix ReadyFlow, Cricket , V-Go and MannKind Corporation are our trademarks in the United States.
If United Therapeutics reduces its commercial emphasis on Tyvaso DPI, our revenues could decline materially.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
Our products, product candidates and technology may not be able to compete effectively or may be rendered obsolete.
+7 more — sign up free →
REMOVED
As of February 14, 2025, there were 303,591,344 shares of the registrant s Common Stock outstanding.
Afrezza, Technosphere , BluHale , Dreamboat , Cricket and V-Go, and MannKind Corporation are our trademarks in the United States.
Our products and product candidates may be rendered obsolete by rapid technological change.
We are a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
Our signature technologies Technosphere dry-powder formulations and Dreamboat inhalation devices offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →